Abstract
Leukocyte telomere length (LTL) shortening is found in a number of age-related diseases, including type 2 diabetes (T2DM). In this study its possible association with mortality was analyzed in a sample of 568 T2DM patients (mean age 65.9 ± 9 years), who were followed for a median of 10.2 years (interquartile range 2.2). A number of demographic, laboratory and clinical parameters determined at baseline were evaluated as mortality risk factors. LTL was measured by quantitative real-time PCR and reported as T/S (telomere-to-single copy gene ratio). Age, gender, creatinine, diabetes duration at baseline, and LTL were significantly different between T2DM patients who were dead and alive at follow-up. In the Cox regression analysis adjusted for the confounding variables, shorter LTL, older age, and longer disease duration significantly increased the risk of all-cause mortality (HR = 3.45, 95%CI 1.02-12.5, p = 0.004). Kaplan-Maier analysis also found a different cumulative mortality risk for patients having an LTL shorter than the median (T/S ≤ 0.04) and disease duration longer than the median (>10 years) (log-rank = 11.02, p = 0.011). Time-dependent mortality risk stratification showed that T2DM duration and LTL combined was a fairly good predictor of mortality over the first 76 months of follow-up. In conclusion, LTL combined with clinical parameters can provide additive prognostic information on mortality risk in T2DM patients.
| Original language | English |
|---|---|
| Pages (from-to) | 50835-50844 |
| Number of pages | 10 |
| Journal | Oncotarget |
| Volume | 7 |
| Issue number | 32 |
| DOIs | |
| Publication status | Published - Aug 1 2016 |
Fingerprint
Keywords
- Aging
- Gerotarget
- Mortality
- Telomere shortening
- Type 2 diabetes
ASJC Scopus subject areas
- Oncology
Cite this
Leukocyte telomere length and mortality risk in patients with type 2 diabetes. / Bonfigli, Anna Rita; Spazzafumo, Liana; Prattichizzo, Francesco; Bonafè, Massimiliano; Mensà, Emanuela; Micolucci, Luigina; Giuliani, Angelica; Fabbietti, Paolo; Testa, Roberto; Boemi, Massimo; Lattanzio, Fabrizia; Olivieri, Fabiola.
In: Oncotarget, Vol. 7, No. 32, 01.08.2016, p. 50835-50844.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Leukocyte telomere length and mortality risk in patients with type 2 diabetes
AU - Bonfigli, Anna Rita
AU - Spazzafumo, Liana
AU - Prattichizzo, Francesco
AU - Bonafè, Massimiliano
AU - Mensà, Emanuela
AU - Micolucci, Luigina
AU - Giuliani, Angelica
AU - Fabbietti, Paolo
AU - Testa, Roberto
AU - Boemi, Massimo
AU - Lattanzio, Fabrizia
AU - Olivieri, Fabiola
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Leukocyte telomere length (LTL) shortening is found in a number of age-related diseases, including type 2 diabetes (T2DM). In this study its possible association with mortality was analyzed in a sample of 568 T2DM patients (mean age 65.9 ± 9 years), who were followed for a median of 10.2 years (interquartile range 2.2). A number of demographic, laboratory and clinical parameters determined at baseline were evaluated as mortality risk factors. LTL was measured by quantitative real-time PCR and reported as T/S (telomere-to-single copy gene ratio). Age, gender, creatinine, diabetes duration at baseline, and LTL were significantly different between T2DM patients who were dead and alive at follow-up. In the Cox regression analysis adjusted for the confounding variables, shorter LTL, older age, and longer disease duration significantly increased the risk of all-cause mortality (HR = 3.45, 95%CI 1.02-12.5, p = 0.004). Kaplan-Maier analysis also found a different cumulative mortality risk for patients having an LTL shorter than the median (T/S ≤ 0.04) and disease duration longer than the median (>10 years) (log-rank = 11.02, p = 0.011). Time-dependent mortality risk stratification showed that T2DM duration and LTL combined was a fairly good predictor of mortality over the first 76 months of follow-up. In conclusion, LTL combined with clinical parameters can provide additive prognostic information on mortality risk in T2DM patients.
AB - Leukocyte telomere length (LTL) shortening is found in a number of age-related diseases, including type 2 diabetes (T2DM). In this study its possible association with mortality was analyzed in a sample of 568 T2DM patients (mean age 65.9 ± 9 years), who were followed for a median of 10.2 years (interquartile range 2.2). A number of demographic, laboratory and clinical parameters determined at baseline were evaluated as mortality risk factors. LTL was measured by quantitative real-time PCR and reported as T/S (telomere-to-single copy gene ratio). Age, gender, creatinine, diabetes duration at baseline, and LTL were significantly different between T2DM patients who were dead and alive at follow-up. In the Cox regression analysis adjusted for the confounding variables, shorter LTL, older age, and longer disease duration significantly increased the risk of all-cause mortality (HR = 3.45, 95%CI 1.02-12.5, p = 0.004). Kaplan-Maier analysis also found a different cumulative mortality risk for patients having an LTL shorter than the median (T/S ≤ 0.04) and disease duration longer than the median (>10 years) (log-rank = 11.02, p = 0.011). Time-dependent mortality risk stratification showed that T2DM duration and LTL combined was a fairly good predictor of mortality over the first 76 months of follow-up. In conclusion, LTL combined with clinical parameters can provide additive prognostic information on mortality risk in T2DM patients.
KW - Aging
KW - Gerotarget
KW - Mortality
KW - Telomere shortening
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=84982286100&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982286100&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.10615
DO - 10.18632/oncotarget.10615
M3 - Article
AN - SCOPUS:84982286100
VL - 7
SP - 50835
EP - 50844
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 32
ER -